Immunology

World Psoriasis Day 2024: Celebrating the invaluable role of family

Borysiuk Viktor (External) — Tue, 29 Oct 2024 13:07:51 +0000

World Psoriasis Day 2024: Celebrating the invaluable role of family

Snauwaert Adriaan, Immuno Global Communication

Borysiuk Vikto… Tue 29/10/2024 - 14:07

Today, Tuesday, 29th October, marks World Psoriasis Day. For more than a decade, the global community has come together on this day to raise awareness and unite in their support of people living with psoriasis and psoriatic arthritis.

Each year, the International Federation of Psoriasis Associations (IFPA) selects a theme for World Psoriasis Day. This year’s theme, ‘Psoriatic Disease and the Family’, aims to raise awareness of the impact living with psoriasis and psoriatic arthritis can have on both people living with these diseases and their family members.

To mark World Psoriasis Day and this year’s theme, we had the honor of an insightful conversation with Caroline, who lives with psoriasis and psoriatic arthritis.

Diagnosed with plaque psoriasis at age 9, Caroline initially received creams for symptom relief. At 19, she was also diagnosed with psoriatic arthritis. For over twenty years, Caroline struggled to manage both her psoriasis and psoriatic arthritis, which sometimes resulted in extended hospital stays. Caroline’s journey was transformed by the support and encouragement of her dermatologist. This dedication and care made a world of difference in her life. Additionally, by connecting with others who faced similar challenges and actively engaging with patient advocacy groups, Caroline discovered a wealth of knowledge and support. These connections and the community supported her to live well with psoriatic disease.

Our conversation with Caroline emphasized the important role family members can play in helping their loved ones thrive while living with psoriatic disease, offering valuable insights into the power of support and understanding.

From a day-to-day perspective, what have been the main challenges of living with psoriasis and psoriatic arthritis?

Psoriasis affects everything. The constant itching, the bleeding, the ugliness of it. Psoriasis dictates everything, and I had to learn to cover it up quite cleverly. I couldn’t wear nice dresses and shorts and would avoid dark jackets.
For a while, I had a futile feeling that nothing could be done. It is only when I look back now that I realize how deeply psoriasis and psoriatic arthritis affected me – I can’t believe that it is only in the last couple of years that I have been able to wear shorts and short sleeves.

What practical or emotional support can family members provide to someone living with psoriasis and psoriatic arthritis?

Family support is really important, particularly the practical support they provide. The itch with psoriasis is terrible, so buying or helping to apply creams and lotions that will tackle this is a really simple way family members can support someone living with psoriasis or psoriatic arthritis. It is also very easy for someone living with these conditions to get despondent with the thought that their psoriasis or psoriatic arthritis is never going to go away; encouragement from family members to see a dermatologist and keep pushing to get the right care can be hugely important in not giving up hope. Outside of the family, I have personally found that having a strong support network of people who have shared experiences of living with psoriasis or psoriatic arthritis has taught me so much – from simply picking up tips to being surrounded by people who know exactly what you are going through.

What support or resources do family members need to deepen their awareness and understanding of the conditions?

Education is empowerment – there is not much family members can do without first educating themselves with the facts. By reading information provided by support groups, family members can arm themselves with knowledge around what psoriasis or psoriatic arthritis is. Additionally, to help family members empathize with their loved ones, I think it is important they hear the realities of living with psoriasis and psoriatic arthritis through patient testimonials.

On World Psoriasis Day 2024, do you have a message to share with families of people living with psoriasis or psoriatic arthritis?

I often hear from people living with chronic psoriasis ‘what is the point of even trying anymore’ – they lose hope when their psoriasis keeps coming back. It gives you comfort to talk to people who know how you’re feeling or have similar experiences, it can be a lifeline. Getting the right doctor, the right diagnosis, the right treatment for you and the right information is so important. Don’t give up. Remember, your support and understanding can make a world of difference providing the strength and hope that family members need to live well with their condition and advocate for themselves.

This World Psoriasis Day, we celebrate the invaluable role of family. We extend our heartfelt gratitude to Caroline for sharing her perspective. Her insights into the potential practical and emotional support that can be provided by family and friends highlight the importance of a strong support network. Together, we aim to raise awareness and deepen understanding of psoriasis and psoriatic arthritis.

about ucb

97 Likes

World Arthritis Day 2024: Informed Choices, Better Outcomes

Andrea_Puletto — Fri, 11 Oct 2024 09:33:47 +0000

World Arthritis Day 2024: Informed Choices, Better Outcomes

Marie Teil, Special Patient Populations

Andrea_Puletto Fri 11/10/2024 - 11:33

On October 12, World Arthritis Day will raise awareness about the realities of living with rheumatic and musculoskeletal diseases (RMDs) and to advocate for better research, education, and patient support. On this day, we are all reminded of our collective responsibility to empower those affected by RMDs – including women and their families who lack concrete data and clear guidance about disease management and treatment, particularly during pregnancy and breastfeeding.

This year’s theme – “Informed Choices, Better Outcomes” – underscores how important it is for people living with RMDs to make informed, evidence-based decisions in partnership with their healthcare teams. Despite the notion that there is an overwhelming amount of information for people with RMDs to access, this is simply not the case for women in their childbearing years who seek robust and relevant data.

So much of my role at ��ֳ� as the Global Head of Women of Childbearing Age has centered around the idea that women need to be protected through research, not from research. We cannot allow women with chronic diseases to be continuously overlooked in clinical research due to perceived liability and risk. Although progress has been made in this space, additional work is needed to create a more balanced view in clinical research.

Supporting World Arthritis Day 2024 and uniting with a global community dedicated to bringing evidence and research to patients is a step in the right direction. There is great power in collaboration, and it begins with facing the challenge head-on and recognizing that there is more work to be done to help improve patient outcomes.

Join us in raising awareness by sharing this post and supporting research initiatives. Together, we can support those living with RMDs and strive for a future where everyone can live their lives to the fullest without fear or uncertainty of how certain disease management decisions will impact them or their families. Thank you for joining us in this important cause.

Follow me, @MarieTeil, on LinkedIn as well as ��ֳ�’s social channels for more updates.

about ucb

arthritis Immunology science World Arthritis Day rheumatic and musculoskeletal diseases RMDs

168 Likes

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Andrea_Puletto — Thu, 26 Sep 2024 12:26:46 +0000

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Snauwaert Adriaan, Immunology Global Communication

Andrea_Puletto Thu 26/09/2024 - 14:26

The American Society for Bone and Mineral Research (ASBMR) Annual Meeting is the largest and most comprehensive global congress dedicated to bone, mineral, and musculoskeletal health. Each year, thousands of leading experts, researchers, and clinicians from around the world gather to exchange knowledge and present the latest breakthroughs in disease management, treatment strategies, and scientific innovation. The 2024 meeting promises to continue this tradition of excellence, offering a unique platform for collaboration and discovery in the ever-evolving field of bone health.

This year, ��ֳ� and Amgen will unveil crucial new data that demonstrate significant advancements in reducing fracture risk and improving bone strength, particularly for patients at high risk of osteoporosis-related fractures. These findings will emphasize the value of new therapeutic approaches in comparison to existing treatments, highlighting their potential to transform osteoporosis care and improve long-term outcomes for patients.

At ��ֳ�, we remain dedicated to advancing research and ensuring patients have access to transformative treatments for osteoporosis. Earlier this year, we caught up with experts to discuss the urgent need to address bone health in aging populations and innovation in osteoporosis treatments. These conversations continue at ASBMR 2024, where we look forward to sharing groundbreaking data and collaborating with the global community to drive progress in bone disease management. Watch the video below!

Complementing this is our Fragility Fracture in Focus podcast series which explores how the P4 Health Spectrum (predictive, preventive, personalized, and participatory) – an increasingly recognized cornerstone of proactive modern medicine – looks to shift focus away from disease to the promotion of a state of wellness. Listen NOW to the Fragility Fractures in Focus podcast to find out more! (For healthcare professionals only).

Stay connected for updates throughout the congress, as we continue to push the boundaries of bone health research and patient care.

about ucb

innovation Immunology science

136 Likes

Redefining immunology care: our pledge to patients and the healthcare community

Vandenbruaene Nathalie — Mon, 23 Sep 2024 08:15:38 +0000

Redefining immunology care: our pledge to patients and the healthcare community

Camille Lee, U.S. Immunology

Vandenbruaene … Mon 23/09/2024 - 10:15

Throughout my career and now in my role as head of U.S. Immunology at ��ֳ�, the stories I hear from patients inspire my work each day. At ��ֳ�, we are dedicated to developing solutions for people living with chronic immune-mediated diseases, including psoriatic arthritis (PsA)—which can affect about 30 percent of people living with psoriasis—as well as lesser-known forms of arthritis like non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).

At the heart of our commitment to addressing gaps in care lies innovation. ��ֳ� is proud to be advancing care with a new solution now available for healthcare providers and their patients.

We know severe rheumatic diseases not only affect physical health but can also impact a person’s ability to take part in everyday activities such as participating in hobbies and recreational activities, socializing with loved ones, and completing household chores. People living with rheumatic diseases often struggle to find long-term disease management solutions that work for them.

That’s why our focus in Immunology at ��ֳ� is developing and providing treatments so that people living with rheumatic or dermatologic diseases, particularly those who have struggled with treatment options, can strive to live their best lives, tackling the activities that once felt like a burden.

��ֳ� is also leading the way in setting higher standards for treatments across immunology. In our PsA clinical trials, we used the American College of Rheumatology (ACR)50 endpoint, which signifies a 50% improvement in symptoms and disease, as a measure of success. This endpoint is more rigorous than the more commonly used ACR20, the 20% improvement marker. By setting this higher standard, we prioritize developing medicines that make a significant impact on patient health.

As our pipeline grows, our approach will continue to evolve to meet the needs of the patient communities we aim to serve. I am confident our bold and exciting research programs will help change the future of immunology care within the next decade.

solutions

rheumatic diseases Immunology psoriatic arthritis non-radiographic axial spondyloarthritis ankylosing spondylitis

122 Likes

Advocating for Change in the Lives of People with Hidradenitis Suppurativa

Vandenbruaene Nathalie — Fri, 12 Apr 2024 08:00:37 +0000

Advocating for Change in the Lives of People with Hidradenitis Suppurativa

Danuta Marchi, External Engagement, Immuno-Dermatology and Rheumatology

Vandenbruaene … Fri 12/04/2024 - 10:00

At ��ֳ�, we are committed to improving the lives of people living with hidradenitis suppurativa (HS), a chronic, painful, inflammatory skin condition that can have a significant and detrimental impact on patients’ lives.

Today, there are several barriers for people living with HS, which can impede their ability to live life to the fullest potential. These include insufficient awareness of HS and delays in diagnosis. These factors can impact the timely and appropriate care that people with HS receive. Additionally, the stigma associated with the disease can negatively affect mental wellbeing and interpersonal relationships.1 Addressing these barriers is a crucial step towards improving lives.

A new international report, Call to action: improving the lives of people with hidradenitis suppurativa (HS), published by The Health Policy Partnership (HPP), communicates the condition’s significant impact and advocates for change by highlighting policy and system barriers to better HS care. The report, published in February 2024, was led by HPP with guidance from a multi-disciplinary Steering Committee. It was developed based on literature review as well as some interviews with people living with HS and healthcare professionals. The research focused largely on ten countries - Canada, Denmark, France, Germany, Italy, Japan, the Netherlands, Spain, Sweden and the United Kingdom. The insights from people living with HS contained in the report serves as a powerful call to action for a deeper understanding of the impact of this debilitating disease on patients’ lives.

The report highlights ten priority recommendations including raising awareness of HS among the general public, employers and healthcare professionals. The focus on increased awareness with these audiences aims to mitigate stigma, encourage people to seek care, accommodate the needs of employees living with HS and improve referral rates and the speed of diagnosis. You can read the full list of recommendations in the online report here.

At ��ֳ�, we firmly believe that implementing these recommendations will significantly enhance the lives of people with HS. By collaborating with the community to enact these changes, we can collectively help to ensure that people living with HS receive the necessary care and support they need today and into the future.

This report was developed as part of a project which is led by The Health Policy Partnership with guidance from a multidisciplinary Steering Committee. HPP was commissioned by ��ֳ�, which initiated and funded the project.

solutions

Hidradenitis Suppurativa HS dermatology Immunology

Comment:

Posted by Takieyah Mathis, 17 April 2024

Thank you for bringing a spotlight to this condition!

377 Likes

International Women’s Day 2024: Inspiring Inclusion

Andrea_Puletto — Thu, 07 Mar 2024 13:13:42 +0000

International Women’s Day 2024: Inspiring Inclusion

Marie Teil, Women of Childbearing Age Department

Andrea_Puletto Thu 07/03/2024 - 14:13

On 8 March, International Women’s Day (IWD), ��ֳ� will rally behind the global call to “Inspire Inclusion” – an important message that we proudly support across our organization. When we take a step back to think about what it means to be inclusive – one critical area that is lacking is the inclusion of pregnant and breastfeeding women in clinical trials. Current research tells us that an underrepresentation of women in clinical trials overall can have a significant negative impact on women’s health.

At ��ֳ�, we are steadfast in our commitment to closing the pregnancy gap and accelerating progress in the care of pregnant and breastfeeding women with chronic diseases. In partnership with clinical teams, we strive to address knowledge gaps, collaborate with and inspire physicians and patients around the world to identify potential educational needs.

I was honored to connect with key external stakeholders this past year on behalf of ��ֳ� at different medical congresses, industry events and panels, including the opportunity to provide feedback on the FDA’s proposed Pregnancy Safety Study Framework workshop.

As advocates for women living with chronic diseases who are navigating life changing moments for themselves and their families, we understand how important it is to resolve the lack of understanding about pregnancy and breastfeeding treatment decisions, ensuring women can make better informed decisions based on facts and inclusivity.

On a personal note, I feel very fortunate to be leading such an important initiative as ��ֳ�’s Global Head of Women of Childbearing Age, and every day I am driven to #InspireInclusion and contribute to meaningful progress in this space. Alongside a devoted team, I am embracing this IWD by advocating for and working towards a future where the inclusion of pregnant and breastfeeding women in clinical trials is the norm. In time, we hope that women can make more informed decisions and feel empowered at all ages and stages of their life.

As I look to the year ahead, I am pleased to share that I will be bringing this important conversation to DIA Global in June. I'm eager to talk about our work towards early data generation for pregnant and lactating women living with chronic diseases.

Also, as co-chair of the global independent commission, BRIDGE (Better Research, Information and Data Generation for Empowerment) – I look forward to continuing to help elevate these important conversations and deliver practical and action-oriented solutions to overcome information gaps that affect women’s health — the first of which will be detailed in a report due in early 2024.
Follow me, @MarieTeil, on LinkedIn as well as ��ֳ�’s social channels for more updates.

about ucb

Immunology WoCBA International Women's Day

415 Likes

Time to Focus on Hidradenitis Suppurativa

Vanco Vlastimil (��ֳ� S.A.) — Wed, 08 Feb 2023 08:54:23 +0000

Time to Focus on Hidradenitis Suppurativa

Ingrid Pansar, Global Medical Affairs Hidradenitis Suppurativa

Vanco Vlastimi… Wed 08/02/2023 - 09:54

The 12^th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) takes place this week (February 8–10, 2023) in Florence, Italy. We sat down with Ingrid Pansar, Global Medical Lead, ��ֳ� and Marie Hélène Saintmard, EU Medical Strategy Lead, ��ֳ�, to learn more about the conference and about hidradenitis suppurativa (HS).

What can you tell us about the 12^th Conference of the European Hidradenitis Suppurativa Foundation?

Ingrid Pansar: “The 12^th Conference of the European Hidradenitis Suppurativa Foundation is an important event in the HS calendar taking place in Florence, Italy, between February 8 – 10. The conference brings together scientists and physicians from all over the world to discuss the latest research and innovations. The high-quality hybrid scientific program offers attending delegates the opportunity to hear the latest research on this extremely important skin disease. At ��ֳ�, we have a longstanding commitment to developing and delivering science that will make a difference in the lives of people with immuno-dermatological conditions and we are looking forward to joining the community over the next few days.”

Can you tell us more about HS and some of the challenges for people living with this disease?

Ingrid Pansar: “HS is a chronic, recurring, painful and inflammatory skin disease. The main symptoms are nodules, abscesses, and pus-discharging fistulas which typically occur in the armpits, groin and sensitive areas. People with HS experience flare-ups of the disease as well as severe pain, which can have a major impact on quality of life. HS develops in early adulthood, and affects approximately one percent of the population in most studied countries. The symptoms of pain, discharge and scarring are not only a physical burden since people with HS can also experience stigma and reactions from society in response to their symptoms.”

Can you share more about ��ֳ�’s overall presence at EHSF 2023?

Marie Hélène Saintmard: “We’re pleased to be a gold sponsor of EHSF 2023 and to have a strong scientific presence at the conference. Our activities at this year’s conference include an educational satellite symposium, an oral presentation and three poster presentations which will share our latest updates on HS, including a literature review focusing on patient quality of life and other patient-reported outcomes. In addition, we are looking forward to welcoming delegates to our medical booth, as well as our virtual booth, where the team will be pleased to discuss our research, answer questions, and share details of our growing partnership network.”

What can healthcare professionals expect to hear if they attend ��ֳ�’s educational symposium at EHSF 2023?

Marie Hélène Saintmard: “We are pleased to be hosting an educational satellite symposium for healthcare professionals titled, ‘Exploring the patient journey: why time matters.’ on February 8th, from 12:45 – 13:30 CET. At this symposium, international experts will discuss the disease trajectory of HS and offer healthcare professionals invaluable insights on the patient journey. If you are a healthcare professional attending EHSF 2023, we hope you can join us for this educational session.”

Do you have a final message for delegates attending the conference?

Ingrid Pansar & Marie Hélène Saintmard: “EHSF 2023 offers multiple learning experiences, an outstanding scientific program and opportunities to engage with leading experts in HS. We believe that building strong relationships with the dermatology community is the path toward optimizing treatment outcomes, improving the patient experience, and delivering solutions that will make a real difference. We are excited to join the discussions this year and to stay up to date with the latest high-quality research and the most recent innovations. To the healthcare professionals attending EHSF 2023, we look forward to meeting with you and welcoming you to our medical booth and educational satellite symposium. See you soon.”

Find out more about Hidradenitis Suppurativa on ��ֳ�’s dedicated page: Hidradenitis Suppurativa | ��ֳ�.

about ucb

EHSF European Hidradenitis Suppurativa Foundation Hidradenitis Suppurativa dermatology Immunology

517 Likes

Celebrating the hybrid experience at the 13th International Immunology Summit 2022

Vanco Vlastimil (��ֳ� S.A.) — Thu, 02 Jun 2022 08:31:48 +0000

Celebrating the hybrid experience at the 13th International Immunology Summit 2022

Adriaan Snauwaert, Global Communications & Company Reputation

Vanco Vlastimi… Thu 02/06/2022 - 10:31

Our 13th annual International Immunology Summit recently took place in Prague, where we welcomed healthcare professionals from around the world, both in person and virtually, over a three-day period. The delegates took part in inspiring learning experiences and attended key discussions that centred around important topics within the care community, looking at how healthcare professionals can truly transform the lives of patients living with immunological diseases.

Executive Vice President, Emmanuel Caeymaex, opened the Summit by welcoming delegates, and reinforcing ��ֳ�’s commitment to Immunology. Our co-chairs Dr William Tillett (Consultant Rheumatologist at the Royal National Hospital for Rheumatic Diseases and senior lecturer in the Department of Pharmacy and Pharmacology at the University of Bath, UK) & Dr Andreas Pinter (Director of Clinical Research in the Department of Dermatology, Venereology, and Allergology at Goethe University in Frankfurt am Main, Germany) then continued the Summit with an inspiring introduction, before hosting an interactive panel discussion between different members of the multidisciplinary team, on transforming patient outcomes through collaboration. This team included Maarten de Wit (Chair of the EULAR Study Group for Collaborative Research, and a patient with psoriatic arthritis), Anusha Patel (Embedded Pharmacist for NHS England, a high-cost drugs pharmacist and regional homecare lead pharmacist for NHS Trusts in the East Midlands, UK) and nurse Louise Moore (Advanced Nurse Practitioner and Adjunct Lecturer/Assistant Professor at UCD School of Nursing, Midwifery and Health Systems based at Our Lady's Hospice and Care Services, Harold's Cross, Dublin).

Day two proved just as engaging with a provocative presentation from Laura Coates (Associate Professor and an NIHR Clinician Scientist at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford, UK) and Jo Lambert (Senior Full Professor in Dermatology and Venerology and Academic Chair of the Department of Dermatology at Ghent University, Ghent, Belgium) discussing whether current practices and standards of care in SpA & PsO are enough. Dr Lambert was then joined by Dr Fabian Proft (Rheumatologist and Senior Researcher at the Charité University Hospital Berlin, Germany) as they looked at how we can deliver better patient care in SpA & PsO. The afternoon provided delegates with a more personalised learning journey, featuring ten mixed workshop and masterclass sessions themed around raising the standard of care in patients with IMIDs.

Our final day focused on the future of clinical practice and patient care with Stefano Piaserico (Associate Professor at the University of Padua, Italy and Head of the Regional Centre for Psoriasis) and Ole Ahlehoff (Consultant Interventional Cardiologist at Copenhagen University Hospital Rigshospitalet) delivering the opening session on recognising and treating comorbidities in IMIDs. This was followed by Leonard Witkamp (former Dermatologist and Director of KSYOS TeleMedical Centre) and Aurélie Najm (Clinical Senior Research Fellow in Immunology at the Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, UK) hosting an inspiring discussion on how we will integrate technologies, including wearables and apps into healthcare, and digital hospitals of the future.

Our 13th International Immunology Summit concluded successfully with positive reviews! One delegate who attended in person described the Summit as an “excellent, high quality learning opportunity”, 100% of delegates said they were extremely motivated/motivated, to implement a change in their working practice because of the meeting content, 90% of virtual delegates would recommend the International Immunology Summit to their colleagues.

Relive the action by watching our highlights video:

about ucb

Immunology Summit Immunology

531 Likes

World Psoriasis Day 2021: Uniting for action

eCMSadmin — Fri, 29 Oct 2021 09:00:00 +0000

World Psoriasis Day 2021: Uniting for action

Jeron Evans, Patient Value Immunology & US Solutions

eCMSadmin Fri 29/10/2021 - 11:00

At ��ֳ�, everything we do starts with one simple question: “How will this create value for patients now and in the future?”

Why? Because we have a fundamental, continual commitment to enable patients, their caregivers, and their families to live their best lives. By focusing our immunology work on specific patient populations where we can make a meaningful difference, we move ever closer to achieving this.

Today, on World Psoriasis Day, we stand united with the International Federation of Psoriasis Associations (IFPA) to shine a light on the impact that psoriasis has on patients. Since 1971, IFPA has been effectively advocating for the psoriatic disease community and today its members represent over 60 million people living with psoriatic disease worldwide. IFPA aims to unite, strengthen and lead the global community to improve the lives of people affected by psoriatic disease.

Each year on October 29, World Psoriasis Day allows us to reflect on the important victories that have been achieved by IFPA and its supporters, whilst offering an opportunity to raise awareness of the many challenges and unmet needs still facing those living with psoriatic disease today.

We understand that psoriasis is more than just a skin disease. People with psoriasis can experience feelings of stigmatization, shame, embarrassment, anger and worry and frequently report difficulties at work and disrupted leisure activities. The social and emotional burdens of psoriasis, together with the visible symptoms, can significantly impact patients’ quality of life. By applying these important insights to inform our science, we can seek to deliver new options that can truly address patients’ needs and improve their quality of life.

At ��ֳ�, we are proud to be a long-term supporter of IFPA and of World Psoriasis Day, which this year follows the theme of ‘United’ – a theme that we are pleased to champion. We know that innovation cannot be delivered alone and recognize the importance of our collaborations with the dermatology community to better meet the evolving needs of patients. For this reason, we engage in partnerships with researchers, clinicians, and advocacy groups from around the globe. These partnerships also underpin our ongoing scientific and medical education programs in dermatology.

Today and every day, my ��ֳ� colleagues and I strive to advance science in immunology. By uniting to address patients’ unmet needs, support clinically meaningful research and build strong, collaborative advocacy partnerships, we can all help to make a meaningful difference for people living with psoriasis.

solutions

World Psoriasis Day Immunology IFPA

704 Likes

��ֳ� is proud to partner on a new EU Research Project – ‘HIPPOCRATES’ – to improve diagnostic and therapeutic options for patients living with Psoriatic Arthritis

eCMSadmin — Mon, 05 Jul 2021 00:00:00 +0000

��ֳ� is proud to partner on a new EU Research Project – ‘HIPPOCRATES’ – to improve diagnostic and therapeutic options for patients living with Psoriatic Arthritis

Owen Davies, Patient Value Immunology & US Solutions

eCMSadmin Mon 05/07/2021 - 02:00

Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease that affects joints and other components of the musculoskeletal system, together with skin involvement, in an estimated 5-10 million individuals in the EU. The symptoms of the disease, including pain, joint stiffness and fatigue, can impact many aspects of life, including function and productivity. Overall, it is increasingly recognised that PsA is associated with multiple comorbidities including cardiovascular morbidity and mortality, and depression.

PsA most commonly develops on a background of established skin and/or nail psoriasis; however, it can be difficult to diagnose as there are no diagnostic criteria or laboratory tests available. This can contribute to diagnostic delay and poor outcomes.

The new European project – HIPPOCRATES – brings together 26 European partners, with involvement of patients, clinicians, primary care practitioners, regulators, small and medium enterprises (SMEs) and pharmaceutical companies. The project aims to improve diagnostic and therapeutic options for patients living with Psoriatic Arthritis. Through gaining a better understanding of the complex interplay between clinical and environmental factors, genotype and molecular pathways, the team aims to enable earlier diagnosis and a more accurate prediction of disease progression.

The HIPPOCRATES project will set up a single integrated database combining the cohorts and datasets of the most important European PsA studies and establish a Europe-wide library of relevant clinical biosamples. HIPPOCRATES will also establish a large, prospective, observational study of 25,000 patients with psoriasis who will be recruited and followed online for the development of PsA, with patient-centric blood sampling at defined intervals.

Furthermore, the team of experts will evaluate and validate newly discovered biomarker signatures for the early diagnosis of PsA, for the identification of psoriasis patients at risk of developing PsA, for the identification of PsA patients at highest risk of damage progression and for personalised or stratified treatment strategies so as to maximise treatment response.

The project will run for a period of five years with a total budget of EUR 21 million provided by the Innovative Medicines Initiative (IMI 2), a Joint Undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Of the total budget, 50% are contributed by the EFPIA partners (Novartis [EFPIA lead], ��ֳ� [EFPIA Co-lead], Pfizer and BMS) and 50% by the EU.

Formed as a transdisciplinary consortium, the project team comprises 26 partner institutions from Belgium, Denmark, Germany, Ireland, Italy, Spain, Sweden, Switzerland, the Netherlands, the United Kingdom and the United States of America. Led by University College Dublin, the partners contribute a diverse range of backgrounds, including clinical, scientific, data analytics, ethics, patient participation, as well as SME and pharmaceutical industry expertise. ��ֳ� represents one of the EFPIA partners and is the EFPIA co-load in this public-private partnership.

At ��ֳ�, we understand how essential public-private partnerships are to finding novel ways to improve diagnostic and therapeutic options for patients living with severe diseases. Facilitating collaboration between patients, clinicians, regulators, SMEs and pharmaceutical industry is crucial for accelerating the scientific discoveries that will help patients with severe diseases live their lives to their fullest.

We are very proud to partner on this new European project and look forward to contributing our pharmaceutical expertise.

More information can be found at http://hippocrates-imi.eu

innovation

Hippocrates Immunology

725 Likes

Immunology

World Psoriasis Day 2024: Celebrating the invaluable role of family

From a day-to-day perspective, what have been the main challenges of living with psoriasis and psoriatic arthritis?

What practical or emotional support can family members provide to someone living with psoriasis and psoriatic arthritis?

What support or resources do family members need to deepen their awareness and understanding of the conditions?

On World Psoriasis Day 2024, do you have a message to share with families of people living with psoriasis or psoriatic arthritis?

Leave a Comment

World Arthritis Day 2024: Informed Choices, Better Outcomes

Leave a Comment

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Leave a Comment

Redefining immunology care: our pledge to patients and the healthcare community

Leave a Comment

Advocating for Change in the Lives of People with Hidradenitis Suppurativa

Leave a Comment

International Women’s Day 2024: Inspiring Inclusion

Leave a Comment

Time to Focus on Hidradenitis Suppurativa

Leave a Comment

Celebrating the hybrid experience at the 13th International Immunology Summit 2022

Leave a Comment

World Psoriasis Day 2021: Uniting for action

Leave a Comment

��ֳ� is proud to partner on a new EU Research Project – ‘HIPPOCRATES’ – to improve diagnostic and therapeutic options for patients living with Psoriatic Arthritis

Leave a Comment

Immunology

World Psoriasis Day 2024: Celebrating the invaluable role of family

From a day-to-day perspective, what have been the main challenges of living with psoriasis and psoriatic arthritis?

What practical or emotional support can family members provide to someone living with psoriasis and psoriatic arthritis?

What support or resources do family members need to deepen their awareness and understanding of the conditions?

On World Psoriasis Day 2024, do you have a message to share with families of people living with psoriasis or psoriatic arthritis?

Leave a Comment

World Arthritis Day 2024: Informed Choices, Better Outcomes

Leave a Comment

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Leave a Comment

Redefining immunology care: our pledge to patients and the healthcare community

Leave a Comment

Advocating for Change in the Lives of People with Hidradenitis Suppurativa

Leave a Comment

International Women’s Day 2024: Inspiring Inclusion

Leave a Comment

Time to Focus on Hidradenitis Suppurativa

Leave a Comment

Celebrating the hybrid experience at the 13th International Immunology Summit 2022

Leave a Comment

World Psoriasis Day 2021: Uniting for action

Leave a Comment

������ֳ� is proud to partner on a new EU Research Project – ‘HIPPOCRATES’ – to improve diagnostic and therapeutic options for patients living with Psoriatic Arthritis

Leave a Comment

��ֳ� is proud to partner on a new EU Research Project – ‘HIPPOCRATES’ – to improve diagnostic and therapeutic options for patients living with Psoriatic Arthritis